Africa CDC and PAHO Collaboration: Strengthening Health Access

By Crystal Lubbe

October 30, 2024

The article from the Africa Centres for Disease Control and Prevention (Africa CDC) website, titled “PAHO and Africa CDC strengthen collaboration to address access to essential medicines and vaccines,” emphasises a vital partnership aimed at improving access to essential medicines and vaccines. This collaboration signifies a commitment to enhance health outcomes in both Africa and the Americas.

Africa CDC and PAHO Partnership Agreement

On September 20, 2024, Pan American Health Organization (PAHO) and Africa CDC agreed to collaborate on equitable access to vaccines and health technologies during Africa CDC’s first official visit to PAHO in Washington, D.C.

PAHO and Africa CDC Collaboration Objectives

The partnership prioritises equitable access by enhancing regional regulatory, innovation, and production mechanisms to improve access to essential medicines and vaccines in Africa and the Americas. Furthermore, it aims to enhance regional manufacturing capacities through initiatives like the African Pooled Procurement Mechanism (APPM) and the Partnerships for African Vaccine Manufacturing (PAVM). PAVM aims to empower African vaccine manufacturing to provide over 60% of the continent’s vaccine needs by 2040.

Key Areas of Cooperation

Pooled Procurement Mechanism: PAHO will share its expertise on operationalising regional revolving funds. Therefore, supporting Africa CDC in implementing the APPM. This mechanism is intended to improve access to quality and affordable health products and promote local manufacturing.
Regulatory and Production Strategies: The discussions focused on demand consolidation, planning, quality, and logistics. Further also strengthening regulatory and regional production strategies to improve access to essential medicines.
Research and Innovation: Advancing research, innovation, and digital transformation of health systems to effectively address public health challenges.
Emergency Response: The collaboration will build resilience by improving preparedness and response to health emergencies, including the ongoing Mpox outbreak. Africa CDC briefed PAHO on the Mpox continental response plan, which emphasises access to lifesaving vaccines.

Statements from Leaders

Dr. Jarbas Barbosa, PAHO Director, highlighted the objective of cultivating a more resilient region by enhancing regional manufacturing capabilities. Therefore, ultimately decreasing reliance on global interventions during crucial emergencies. On the other hand, Dr. Jean Kaseya, Africa CDC Director General, emphasised the significance of this partnership in advancing health outcomes through collaborative efforts.

Broader Strategic Priorities

The collaboration seeks to promote broader strategic priorities in both regions, with a focus on improving and safeguarding health. This includes exploring opportunities for south-south cooperation that can address health challenges and capitalize on the strengths of both regions.

In conclusion,this partnership aims to enhance health outcomes, access to essential products, and strengthen health systems in Africa and the Americas. The commitment to addressing access to essential medicines and vaccines reflects a strategic approach to global health collaboration.

Reference url

Recent Posts

Canada Drug Agency Plan
          

Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030

🚀 Are you ready to explore the future of healthcare in Canada?

The newly launched **Canada Drug Agency Plan** aims to redefine how we approach drug and health technology decisions, focusing on anticipation, innovation, and transformation to boost health outcomes for all Canadians. This five-year strategic initiative captures essential insights needed for a healthier nation amid evolving pharmaceutical policies.

Curious how this plan could impact the healthcare landscape? Dive into the full article to learn more!

#SyenzaNews #HealthcarePolicy #HealthTech #Innovation

hepatitis C treatment options
       

VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options

🔍 Are you curious about the latest advancements in hepatitis C treatment options?

The groundbreaking VIETNARMS trial reveals that sofosbuvir-daclatasvir offers a comparable efficacy to sofosbuvir-velpatasvir while exploring innovative strategies that could reshape treatment accessibility and affordability. With cure rates exceeding 90%, these findings hold promise for improving outcomes, especially in underserved populations.

Dive into the full article to uncover how these developments could revolutionize hepatitis C care!

#SyenzaNews #globalhealth #HealthcareInnovation

hepatitis C treatment
    

Revolutionizing Hepatitis C Treatment: The Transformative Role of Direct-Acting Antivirals

💡 How are direct-acting antivirals (DAAs) revolutionizing hepatitis C treatment?

The rise of DAAs has led to cure rates between 95-99%, shifting the landscape of hepatitis C care. As we strive for the global eradication goal by 2030, understanding the market dynamics and expanding patient access becomes crucial.

Dive into the article to explore how these advancements impact health economics and public health strategies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.